- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Laser Trabeculoplasty, a Potential Therapy For Treatment of Glaucoma
Laser trabeculoplasty has been a well-proven therapeutic option in glaucoma management and gained popularity more recently. In a recent study, researchers have found that selective laser trabeculoplasty (SLT) is effective in lowering intraocular pressure with satisfactory success rates even after a single SLT. The research has been published on the Current Opinion in Ophthalmology in March 2021 issue.
Selective laser trabeculoplasty is a therapy independent of patient adherence, which is typically low among glaucoma patients. Consequently, the number of studies on SLT has multiplied throughout the past years. Previous studies of selective laser trabeculoplasty (SLT) have shown success rates ranging from 18% to 88%, but the study designs have varied. Therefore, Dr Töteberg-Harms and his team conducted a study to provide an overview of studies on SLT from the last 12 months. The researchers reviewed 32 manuscripts on selective laser trabeculoplasty (SLT) published between June 2019 and May 2021.
Key findings of the study were:
- The researchers reported that the treatment success can range from 88% at 1 year to 18% at 3 years. However, they also noted that the study designs differ and, many studies are not directly comparable.
- In younger patients, they noted that the angles with greater angle pigmentation, higher baseline intraocular pressure (IOP), and eyes that had topical steroids or nonsteroid anti-inflammatory medications post-op, were associated with better outcomes.
- Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension (LiGHT), a prospective, multicentric randomized controlled trial. Upon evaluating the LiGHT trial, the researchers have reported that the findings demonstrated good efficacy of SLT – 75% of the eyes achieved their target pressure without drops and 58% after a single SLT. It further showed that SLT patients had lower visual field progression (16.9%) compared with patients in the medically treated group (26.2%).
The authors concluded, "SLT has proven to be effective in lowering IOP with satisfactory success rates even after single SLT. SLT is repeatable independent of patient's adherence".
The commentator, Dr Joseph M. Ortiz MD further added, "I agree with the authors' conclusion that SLT has attained a secure place in glaucoma management. Patients who are unable to take their medications because of physical limitations, inability to afford medication, or poor adherence should be strongly encouraged to have the procedure".
For further information:
DOI: 10.1097/ICU.0000000000000732
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751